BioPharmSignal logoBioPharmSignal

Biotech News

Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates

Gyre Therapeutics (GYRE)Gyre TherapeuticsEarnings

Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), a U.S.

Related news

AVTXAvalo Therapeutics2026-11-05 12:00 EST

Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

SNGXSOLIGENIX2026-11-06 12:30 EST

Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results

ZURAZura Bio2026-10-27 11:30 EST

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

MLTXMoonLake Immunotherapeutics2026-11-04 12:00 EST

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

REGNRegeneron Pharmaceuticals2026-10-30 10:30 EST

Regeneron Reports Third Quarter 2026 Financial and Operating Results

SABSSAB Biotherapeutics2026-10-29 12:30 EST

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET

KNSAKiniksa2026-10-27 11:30 EST

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

View all latest news

Gyre Therapeutics

Fibrosis and Inflammation Franchise Gyre Therapeutics is a commercial-stage biopharmaceutical company operating in the United States and China. Its small-molecule portfolio is centered on organ fibrosis and inflammatory diseases. Commercial Products in China Gyre Pharmaceuticals commercializes ETUARY, a pirfenidone therapy for idiopathic...

Recent company news

GYREGyre Therapeutics2026-11-05 21:08 EST

Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates

GYREGyre Therapeutics2026-09-03 11:00 EST

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

GYREGyre Therapeutics2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

GYREGyre Therapeutics2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

GYREGyre Therapeutics2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Stock data

Close
4.01 USD
Market cap
539.48M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States